Dermata Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

DRMA$0.77+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Par Value	Capital	Deficit	Equity
Balance at December 31, 2025	2,660,110	$266	$79,457,010	$(73,233,896)	$6,223,380
Issuance of Common Stock from ATM sales, net of issuance costs	824,283	82	1,993,969	-	1,994,051
Issuance of Common Stock upon exercise of pre-funded warrants	537,750	54	(54)	-	-
Stock-based compensation	-	-	43,278	-	43,278
Net loss	-	-	-	(1,847,706)	(1,847,706)
Balance at March 31, 2026	4,022,143	$402	$81,494,203	$(75,081,602)	$6,413,003

Statements of Stockholders’ Equity

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Par Value	Capital	Deficit	Equity
Balance at December 31, 2024	251,725	$25	$67,236,408	$(65,675,339)	$1,561,094
Issuance of Common Stock and warrants from January 2025 PIPE, net of issuance costs	193,539	19	2,254,702	-	2,254,721
Issuance of Common Stock upon exercise of pre-funded warrants	97,746	10	967	-	977
Issuance of Common Stock and warrants from March 2025 Warrant Inducement, net of issuance costs	60,200	6	5,750,822	-	5,750,828
Stock-based compensation	-	-	37,189	-	37,189
Net loss	-	-	-	(2,303,587)	(2,303,587)
Balance at March 31, 2025	603,210	$60	$75,280,088	$(67,978,926)	$7,301,222

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.